Abstract
It is well established that an increase of n-6 polyunsaturated (i.e. arachidonic and arachidonic-converted linoleic acids) fat dietary intake enhances carcinogenesis and promotes tumorigenesis through oxidative metabolism. The Cyclooxygenase (COX) and Lipoxygenase (LOX) enzymes mediate the oxidative metabolism of n-6 polyunsaturated fatty acids and generate a cascade of biological active molecules. Nonsteroidal antinflammatory drugs (NSAIDs) modulating arachidonic acid (AA) metabolism have been utilized in cancer chemoprevention. The gastrolesivity of a prolonged use of nonselective NSAIDs, due to the COX inhibition, an important housekeeping gene of the gastrointestinal system, contraindicated their use in chemoprevention. Moreover, cardiovascular side effects emerged in the long-term use of COX-2 specific inhibitors rising doubts on their use for cancer chemoprevention. This evidence renewed the interest into other AA-metabolizing pathways relevant in inflammation and carcinogenesis. Here, the role of the LOXs pathways in carcinogenesis is reviewed. Inhibition of the LOX pathways, alone or in association with COX-2 pathway, appears to be a promising field for detecting new molecular target and engineering new chemopreventive strategies on cancer.
Keywords: Lipoxygenase inhibitors, cancer prevention, cellular senescence
Current Pharmaceutical Design
Title: Lipoxygenase Inhibitors for Cancer Prevention: Promises and Risks
Volume: 16 Issue: 6
Author(s): Cecilia Menna, Fabiola Olivieri, Alfonso Catalano and Antonio Procopio
Affiliation:
Keywords: Lipoxygenase inhibitors, cancer prevention, cellular senescence
Abstract: It is well established that an increase of n-6 polyunsaturated (i.e. arachidonic and arachidonic-converted linoleic acids) fat dietary intake enhances carcinogenesis and promotes tumorigenesis through oxidative metabolism. The Cyclooxygenase (COX) and Lipoxygenase (LOX) enzymes mediate the oxidative metabolism of n-6 polyunsaturated fatty acids and generate a cascade of biological active molecules. Nonsteroidal antinflammatory drugs (NSAIDs) modulating arachidonic acid (AA) metabolism have been utilized in cancer chemoprevention. The gastrolesivity of a prolonged use of nonselective NSAIDs, due to the COX inhibition, an important housekeeping gene of the gastrointestinal system, contraindicated their use in chemoprevention. Moreover, cardiovascular side effects emerged in the long-term use of COX-2 specific inhibitors rising doubts on their use for cancer chemoprevention. This evidence renewed the interest into other AA-metabolizing pathways relevant in inflammation and carcinogenesis. Here, the role of the LOXs pathways in carcinogenesis is reviewed. Inhibition of the LOX pathways, alone or in association with COX-2 pathway, appears to be a promising field for detecting new molecular target and engineering new chemopreventive strategies on cancer.
Export Options
About this article
Cite this article as:
Menna Cecilia, Olivieri Fabiola, Catalano Alfonso and Procopio Antonio, Lipoxygenase Inhibitors for Cancer Prevention: Promises and Risks, Current Pharmaceutical Design 2010; 16 (6) . https://dx.doi.org/10.2174/138161210790883822
DOI https://dx.doi.org/10.2174/138161210790883822 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: Drug Targets and Biomarkers for Obstetric/Gynecologic/Reproductive Diseases
Current Drug Targets Patent Selections:
Recent Patents on Regenerative Medicine Potassium Channels are a New Target Field in Anticancer Drug Design
Recent Patents on Anti-Cancer Drug Discovery Roles of Medicinal Plants and Constituents in Gynecological Cancer Therapy: Current Literature and Future Directions
Current Topics in Medicinal Chemistry Histone Deacetylase Inhibitors: An Attractive Strategy for Cancer Therapy
Current Medicinal Chemistry Inhibiting the Enzymes of the Endothelin and Renin-Angiotensin Systems in Cancer
Current Enzyme Inhibition Management of Unusual Not Scar Ectopic Pregnancy: A Multicentre Retrospective Case Series
Current Women`s Health Reviews Epigenetic Regulation of Epithelial to Mesenchymal Transition
Current Cancer Drug Targets Fulvestrant - A Novel Endocrine Therapy for Breast Cancer
Current Medicinal Chemistry Microbicides for Prevention of Transmission of Sexually Transmitted Diseases
Current Pharmaceutical Design Cucurbitacin B Enhances the Anticancer Effect of Imatinib Mesylate Through Inhibition of MMP-2 Expression in MCF-7 and SW480 Tumor Cell Lines
Anti-Cancer Agents in Medicinal Chemistry A Review of the Recent Developments in Synthetic Anti-Breast Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Heterocyclic Moieties as HDAC Inhibitors: Role in Cancer Therapeutics
Mini-Reviews in Medicinal Chemistry Postmenopausal Hormone Therapy
Current Women`s Health Reviews Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry Blind Snipers: Relevant Off Target Effects of Non-chemotherapeutic Agents in Oncology: Review of the Literature
Reviews on Recent Clinical Trials Diabetes, Cancer and Treatment – A Mini-Review
Current Drug Safety Interactions of the Aryl Hydrocarbon Receptor with Inflammatory Mediators:Beyond CYP1A Regulation
Current Drug Metabolism Current Issues on Epileptic Women
Current Pharmaceutical Design Different 6-Aryl-Fulvenes Exert Anti-proliferative effects on Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry